Newtyn Management, LLC
Q3 2025 13F-HR Holdings
Net value change ($000)
+156,952
(23.8%)
New positions
6
Sold out positions
7
Turnover %
20.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| AD | 67,514 | NEW |
| INDV | 62,835 | 163.5% |
| QDEL | 30,358 | 61.8% |
| TBPH | 17,671 | 32.4% |
| AIV | 16,653 | 37.1% |
| GLIBA | 13,623 | NEW |
| NVRI | 12,795 | 147.3% |
| 89bio, Inc. | 9,796 | 498.8% |
| VISN | 9,288 | NEW |
| RHLD | 9,274 | 105.8% |
Top Reduces (Value $000, Stocks/ETFs)
| CNNE | -29,790 | -32.3% |
| MRP | -23,011 | -100.0% |
| PAR | -12,663 | -43.0% |
| BV | -10,598 | -25.6% |
| DV | -10,479 | -100.0% |
| CMP | -9,082 | -35.4% |
| Sage Therapeutics, Inc. | -6,384 | -100.0% |
| AMN | -5,933 | -100.0% |
| iTeos Therapeutics, Inc. | -5,657 | -100.0% |
| MITK | -4,801 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|